Raphaël Serreau

Prof. Raphaël Serreau

Addictologie, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2009 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
OMOlivier Mir
Olivier Mir
PBP. Berveiller
P. Berveiller
FGF. Goffinet
F. Goffinet
JTJ.-M. Treluyer
J.-M. Treluyer
RSRaphaël Serreau
Raphaël Serreau
RRRoman Rouzier
Roman Rouzier
The co-occurrence of breast cancer and pregnancy is an important issue for the forthcoming years, given the trend for women to postpone childbearing [1]. Although the use of doxorubicin- and epirubicin-based regimens appear quite safe in the second and third trimesters of pregnancy [2, 3], little is known on the safety of taxanes, with only 14 cases found in our literature review 2 years ago [1].

1 September 2013 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
DHDominique Hubert
Dominique Hubert
HRHélène Réglier-Poupet
Hélène Réglier-Poupet
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus
AFAgnès Ferroni
Agnès Ferroni
MBMuriel Le Bourgeois
Muriel Le Bourgeois
JCJoël Coste
Joël Coste

28 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJeanne Sibiude
Jeanne Sibiude
JGJean Guibourdenche
Jean Guibourdenche
MDMarie-Danielle Dionne
Marie-Danielle Dionne
CRCamille Le Ray
Camille Le Ray
OAOlivia Anselem
Olivia Anselem
VTVassilis Tsatsaris
Vassilis Tsatsaris
The circulating concentration of PlGF is reported to be lower in patients experiencing preeclampsia and patients delivering a small for gestational age (SGA) neonate. To evaluate the predictive value of circulating PlGF for preeclampsia and adverse outcome in patients with suspected preeclampsia or intrauterine growth restriction (IUGR). A double blind prospective study. We enrolled 96 women for suspected preeclampsia or IUGR, and measured plasma levels of PlGF (Triage®) at enrolment. We defined adverse outcome as severe preeclampsia, SGA neonate (<10th centile) or elective delivery for maternal or fetal complication. Severe adverse outcome was studied among patients included <34 weeks gestation (WG) and defined as eclampsia, HELLP syndrome, very SGA (<3rd centile) or elective delivery <34 WG. The mean logtransformed PlGF level was lower for women who experienced preeclampsia (2.9 vs 3.7, p = 0.02), and was markedly lower for patients who experienced adverse outcome (2.9 vs 4.3, p<0.001). The odds of presenting an adverse outcome were higher for the lowest tertile of PlGF compared to the higher (OR = 13 , 95% CI [3–50]). For severe adverse outcome, odds were respectively for the lowest and intermediate tertile as compared with the higher tertile : OR = 216, 95% CI [18–2571]; and OR = 17, 95% CI [3–94]. When included <34 WG, patients with a PlGF level 5th centile experienced a severe adverse outcome within 15 days (5%). Among women with suspected preeclampsia or IUGR, PlGF helps identify women who will experience an adverse outcome and those who will not within a time period of 15 days.

1 February 2018 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
MBManfred Ballmann
Manfred Ballmann
DHDominique Hubert
Dominique Hubert
BABaroukh M Assael
Baroukh M Assael
DSDoris Staab
Doris Staab
AHAlexandra Hebestreit
Alexandra Hebestreit
MGManfred Götz
Manfred Götz

20 April 2005 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
RSRaphaël Serreau
Raphaël Serreau
DLDominique Luton
Dominique Luton
MMMarie‐Alice Macher
Marie‐Alice Macher
ADAnne‐Lise Delezoide
Anne‐Lise Delezoide
CGCatherine Garel
Catherine Garel
Evelyne Jacqz-AigrainEvelyne Jacqz-Aigrain
Evelyne Jacqz-Aigrain

21 June 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
GMGatien Serge Messire
Gatien Serge Messire
RSRaphaël Serreau
Raphaël Serreau
Sabine Berteina-RaboinSabine Berteina-Raboin
Sabine Berteina-Raboin
Here we have chosen to highlight the main natural molecules extracted from Camellia sinensis, Andrographis paniculata, and Curcuma longa that may possess antioxidant activities of interest for skin protection. The molecules involved in the antioxidant process are, respectively, catechins derivatives, in particular, EGCG, andrographolide, and its derivatives, as well as various curcuminoids. These plants are generally used as beverages for Camellia sinensis (tea tree), as dietary supplements, or as spices. The molecules they contain are known for their diverse therapeutic activities, including anti-inflammatory, antimicrobial, anti-cancer, antidiabetic, and dermatological treatment. Their common antioxidant activities and therapeutic applications are widely documented, but their use in cosmetics is more recent. We will see that the use of pharmacomodulated derivatives, the addition of co-antioxidants, and the use of various formulations enable better skin penetration and greater ingredient stability. In this review, we will endeavor to compile the cosmetic uses of these natural molecules of interest and the various structural modulations reported with the aim of improving their bioavailability as well as establishing their different mechanisms of action.